Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2005-11-18
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 200
- Registration Number
- NCT00209833
- Locations
- 🇩🇪
Hannover Medical School, Hannover, Germany
Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- European Mantle Cell Lymphoma Network
- Target Recruit Count
- 360
- Registration Number
- NCT00209222
- Locations
- 🇫🇷
Groupe D´Etudes des Lymphomes De l´Adulte (GELA), Paris, France
🇩🇪German Low Grade Study Group (Glsg), Munich, Germany
🇵🇱The Maria Sklodowska Memorial, Cancer Center - Inst. of Oncology, Warszawa, Poland
Efficacy of G-CSF-Priming in Elderly AML Patients
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2005-10-26
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT00199147
- Locations
- 🇩🇪
University Hospital, Medical Department II, Frankfurt, Germany
German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-08-23
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT00199017
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
- Conditions
- Interventions
- Drug: CyclophosphamideDrug: DexamethasoneDrug: VincristineDrug: DaunorubicinDrug: AsparaginaseDrug: MethotrexateDrug: CytarabineDrug: MercaptopurineDrug: G-CSFDrug: VindesineDrug: EtoposideDrug: PrednisoloneDrug: AdriamycinDrug: ThioguanineDrug: TeniposideProcedure: CNS irradiationProcedure: Mediastinal IrradiationProcedure: Stem cell transplantation (SCT)Drug: IdarubicinDrug: FludarabineDrug: Cladribine
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 1883
- Registration Number
- NCT00198991
- Locations
- 🇩🇪
University of Frankfurt, Medical Dept. II, Frankfurt, Germany
German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 377
- Registration Number
- NCT00198978
- Locations
- 🇩🇪
University of Frankfurt, Medical Dept. II, Frankfurt, Germany
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 720
- Registration Number
- NCT00199069
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- Nicola Goekbuget
- Target Recruit Count
- 650
- Registration Number
- NCT00199082
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-08-23
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00199004
- Locations
- 🇩🇪
University Hospital of Frankfurt, Medical Dept. II, Frankfurt, Germany
Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2007-10-19
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Registration Number
- NCT00199186
- Locations
- 🇩🇪
Medizinische Klinik II, Johann Wolfgang Goethe Universität, Frankfurt/Main, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.